First Manhattan’s 4D Molecular Therapeutics FDMT Stock Holding History

First Manhattan’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-160,392	Closed	-$2.04M	–	1478
2023 Q3	$2.04M	Buy	160,392 +15,900	+11%	+$266K	0.01%	302
2023 Q2	$2.61M	Buy	+144,492	New	+$2.66M	0.01%	273

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan's FDMT Position: Q4 2023 in Review

First Manhattan sold out of 4D Molecular Therapeutics (FDMT) in Q4 2023, closing a stake of 160,392 shares — an estimated $2.04M sold.

First Manhattan first reported a position in FDMT in Q2 2023 and held it in 2 quarters. The position peaked at $2.61M in Q2 2023. 111 funds tracked by Wall St. Rank hold FDMT as of Q4 2023.

First Manhattan reported no remaining 4D Molecular Therapeutics position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 160,392 4D Molecular Therapeutics shares in Q4 2023, an estimated $2.04M.
First Manhattan first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 2 quarters.
First Manhattan's 4D Molecular Therapeutics position peaked at $2.61M in Q2 2023.
111 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.